Patents by Inventor Hongwen M. Rivers

Hongwen M. Rivers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TIME RELEASED BIODEGRADABLE OR BIOERODIBLE MICROSPHERES OR MICROPARTICLES SUSPENDED IN A SOLIDIFYING DEPOT-FORMING INJECTABLE DRUG FORMULATION
    Publication number: 20230390212
    Abstract: A composite drug delivery material may be injected into an eye of a human being or mammal to provide sustained delivery of the drug. A composite drug delivery material may include a plurality of microparticles dispersed in a media composition. The microparticles may contain a drug and a coating comprising a bioerodible material or a biodegradable material, and the media composition includes the drug dispersed in a depot-forming material. The media composition may gel or solidify upon injection into the eye.
    Type: Application
    Filed: December 27, 2022
    Publication date: December 7, 2023
    Inventors: David A. Marsh, Hongwen M. Rivers
  • TIME RELEASED BIODEGRADABLE OR BIOERODIBLE MICROSPHERES OR MICROPARTICLES SUSPENDED IN A SOLIDIFYING DEPOT-FORMING INJECTABLE DRUG FORMULATION
    Publication number: 20200297650
    Abstract: A composite drug delivery material may be injected into an eye of a human being or mammal to provide sustained delivery of the drug. A composite drug delivery material may include a plurality of microparticles dispersed in a media composition. The microparticles may contain a drug and a coating comprising a bioerodible material or a biodegradable material, and the media composition includes the drug dispersed in a depot-forming material. The media composition may gel or solidify upon injection into the eye.
    Type: Application
    Filed: December 19, 2019
    Publication date: September 24, 2020
    Inventors: David A. Marsh, Hongwen M. Rivers
  • Sustained release siRNA for ocular drug delivery
    Patent number: 9480646
    Abstract: The present invention provides an ocular implant of siRNA complexed with a transfection agent such as cationic lipids and short cell penetration peptides, wherein the complex is associated with a biocompatible polymer. The biocompatible polymer includes a polymeric matrix configured to release the complex into the eye of a patient at therapeutic levels for a time sufficient to treat an ocular condition or disease.
    Type: Grant
    Filed: January 29, 2015
    Date of Patent: November 1, 2016
    Assignee: Allergan, Inc.
    Inventors: Hongwen M. Rivers, Lon T. Spada, Michelle Luu
  • SUSTAINED RELEASE siRNA FOR OCULAR DRUG DELIVERY
    Publication number: 20150141348
    Abstract: The present invention provides an ocular implant comprising siRNA complexed with a transfection agent selected from the group consisting of cationic lipids and short cell penetration peptides, wherein said complex is associated with a biocompatible polymer. Said biocompatible polymer comprises a polymeric matrix configured to release said complex into the eye of a patient at therapeutic levels for a time sufficient to treat an ocular condition or disease.
    Type: Application
    Filed: January 29, 2015
    Publication date: May 21, 2015
    Inventors: Hongwen M. Rivers, Lon T. Spada, Michelle Luu
  • Methods, Compositions and Drug Delivery Systems for Intraocular Delivery of siRNA Molecules
    Publication number: 20150141484
    Abstract: Biocompatible intraocular drug delivery systems in the form of an implant for intraocular administration of siRNA molecules. The drug delivery systems may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy among others.
    Type: Application
    Filed: November 18, 2013
    Publication date: May 21, 2015
    Inventors: Robert T. Lyons, Hongwen M. Rivers, John T. Trogden
  • METHOD OF CONTROLLING INITIAL DRUG RELEASE OF siRNA FROM SUSTAINED-RELEASE IMPLANTS
    Publication number: 20150087696
    Abstract: The present invention provides an intraocular implant comprising siRNA combined with a excipient effective to retard the initial release of the siRNA from an implant, wherein said siRNA and excipient is associated with a biocompatible polymer (e.g., a polymeric matrix), configured to release said siRNA into the eye of a patient at therapeutic levels for a time sufficient to treat an ocular condition or disease.
    Type: Application
    Filed: December 2, 2014
    Publication date: March 26, 2015
    Inventors: Hongwen M. Rivers, Lon T. Spada, Michelle Luu
  • Sustained release siRNA for ocular drug delivery
    Patent number: 8946170
    Abstract: An ocular implant comprising siRNA complexed with a transfection agent selected from the group consisting of cationic lipids and short cell penetration peptides, wherein the complex is associated with a biocompatible polymer is described. The biocompatible polymer comprises a polymeric matrix configured to release the complex into the eye of a patient at therapeutic levels for a time sufficient to treat an ocular condition or disease.
    Type: Grant
    Filed: July 20, 2011
    Date of Patent: February 3, 2015
    Assignee: Allergan, Inc.
    Inventors: Hongwen M. Rivers, Lon T. Spada, Michelle Luu
  • AUTOCLAVABLE SUSPENSIONS OF CYCLOSPORIN A FORM 2
    Publication number: 20130123194
    Abstract: Disclosed herein are autoclavable formulations of cyclosporin A Form 2, methods of making such formulations, and methods of treating diseases of the eye with such formulations.
    Type: Application
    Filed: November 14, 2012
    Publication date: May 16, 2013
    Applicant: ALLERGAN, INC.
    Inventors: Wendy M. Blanda, Hongwen M. Rivers, David A. Marsh, Michelle Luu
  • SUSTAINED RELEASE siRNA FOR OCULAR DRUG DELIVERY
    Publication number: 20120022002
    Abstract: The present invention provides an ocular implant comprising siRNA complexed with a transfection agent selected from the group consisting of cationic lipids and short cell penetration peptides, wherein said complex is associated with a biocompatible polymer. Said biocompatible polymer comprises a polymeric matrix configured to release said complex into the eye of a patient at therapeutic levels for a time sufficient to treat an ocular condition or disease.
    Type: Application
    Filed: July 20, 2011
    Publication date: January 26, 2012
    Inventors: Hongwen M. Rivers, Lon T. Spada, Michelle Luu
  • METHOD OF CONTROLLING INITIAL DRUG RELEASE OF siRNA FROM SUSTAINED-RELEASE IMPLANTS
    Publication number: 20120022137
    Abstract: The present invention provides an intraocular implant comprising siRNA combined with a excipient effective to retard the initial release of the siRNA from an implant, wherein said siRNA and excipient is associated with a biocompatible polymer (e.g., a polymeric matrix), configured to release said siRNA into the eye of a patient at therapeutic levels for a time sufficient to treat an ocular condition or disease.
    Type: Application
    Filed: July 20, 2011
    Publication date: January 26, 2012
    Inventors: Hongwen M. Rivers, Lon T. Spada, Michelle Luu